false
--12-31
0001712762
0001712762
2026-11-20
2026-11-20
0001712762
BIAF:CommonStockParValue0.007PerShareMember
2026-11-20
2026-11-20
0001712762
BIAF:WarrantsToPurchaseCommonStockMember
2026-11-20
2026-11-20
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 20, 2026
bioAffinity
Technologies, Inc.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-41463 |
|
46-5211056 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
Number) |
3300
Nacogdoches Road, Suite 216
San
Antonio, Texas 78217
(Address
of principal executive offices, including zip code)
(210)
698-5334
(Registrant’s
telephone number, including area code)
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Title of each class |
|
Trading Symbols |
|
Name of each exchange on which registered |
| Common Stock, par value $0.007 per share |
|
BIAF |
|
The Nasdaq Stock Market LLC
(Nasdaq Capital Market) |
| |
|
|
|
|
| Warrants to purchase Common Stock |
|
BIAFW |
|
The Nasdaq Stock Market LLC
(Nasdaq Capital Market) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
At
the Special Meeting of Stockholders of bioAffinity Technologies, Inc. (the “Company”) held on November 20, 2026 (the “Special
Meeting”), stockholders approved an amendment to the Company’s Certificate of Incorporation to decrease the total number
of authorized shares of common stock, par value $0.007 per share (the “Common Stock”), from 350,000,000 shares to 200,000,000
shares (the “Charter Amendment”). On November 20, 2026, the Company filed the Certificate of Amendment with the Secretary
of State of the State of Delaware, and the Charter Amendment became effective immediately upon filing.
The
foregoing description of the Charter Amendment is qualified in its entirety by reference to the text of the Certificate of Amendment,
a copy of which is attached as Exhibit 3.1 to this Current Report on Form 8-K.
Item
5.07. Submission of Matters to a Vote of Security Holders.
At
the Special Meeting, the Company’s stockholders voted on five proposals, each of which is listed below and described in more detail
in the Company’s Definitive Proxy Statement dated October 23, 2026 (the “Proxy Statement”). With respect to each proposal,
holders of the Company’s Common Stock were entitled to cast one vote per share of Common Stock held as of the close of business
on the record date of September 23, 2026 (the “Record Date”). On the Record Date, there
were 1,166,625 shares of the Company’s Common Stock outstanding and entitled to vote at the Special Meeting.
The
following are the final results of voting on each of the proposals presented at the Special Meeting:
Proposal
No. 1: August Warrant Exercise Proposal
The
stockholders approved the issuance, pursuant to Nasdaq listing rules, of up to an aggregate of 1,128,272 shares of Common Stock issuable
upon exercise of Common Stock purchase warrants issued in connection with the private placement offering that closed on August 14, 2026.
| Votes For | |
Votes Against | |
Abstentions | |
Broker Non-Votes | |
| | 61,862 | |
35,286 | |
834 | |
427,784 | |
Proposal
No. 2: October Warrant Exercise Proposal
The
stockholders approved the issuance, pursuant to Nasdaq listing rules, of up to an aggregate of 980,072 shares of Common Stock issuable
upon exercise of Common Stock purchase warrants issued in connection with the private placement offering that closed on October 8, 2026.
| Votes For | |
Votes Against | |
Abstentions | |
Broker Non-Votes | |
| | 61,180 | |
33,081 | |
3,721 | |
427,784 | |
Proposal
No. 3: Offering Proposal
The
stockholders approved the issuance of securities in one or more non-public offerings in accordance with Nasdaq Marketplace Rule 5635(d).
| Votes For | |
Votes Against | |
Abstentions | |
Broker Non-Votes | |
| | 50,700 | |
28,910 | |
18,372 | |
427,784 | |
Proposal
No. 4: Decrease in Authorized Shares Proposal
The
stockholders approved an amendment to the Company’s Certificate of Incorporation to decrease the total number of authorized shares
of Common Stock from 350,000,000 shares to 200,000,000 shares.
| Votes For | |
Votes Against | | |
Abstentions | |
Broker Non-Votes | |
| | 319,130 | |
149,445 | | |
57,191 | |
- | |
Proposal
No. 5: Adjournment Proposal
The
stockholders approved the adjournment of the Special Meeting to a later date, if necessary or appropriate, to permit further solicitation
and vote of proxies in the event of insufficient votes for, or otherwise in connection with, approval of Proposal Nos. 1, 2, 3 and/or
4. However, such an adjournment was not necessary in light of the approval of Proposal Nos. 1, 2, 3 and 4 at the Special Meeting.
| Votes For | | |
Votes Against | | |
Abstentions | | |
Broker Non-Votes | |
| | 308,230 | | |
| 159,496 | | |
| 58,040 | | |
| - | |
Item
9.01. Financial Statements and Exhibits.
| Exhibit Number |
|
Description |
| 3.1 |
|
Certificate of Amendment to the Certificate of Incorporation of bioAffinity Technologies, Inc., dated November 20, 2026. |
| 104 |
|
Cover Page Interactive Data File (embedded within the XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K
to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: November 20, 2026 |
BIOAFFINITY
TECHNOLOGIES, INC. |
| |
|
| |
By: |
/s/ Maria
Zannes |
| |
Name: |
Maria Zannes |
| |
Title: |
President and Chief
Executive Officer |